NEW YORK (GenomeWeb) – Qiagen has entered into a collaboration and comarketing agreement with Centogene, a German firm focusing on genetic diagnosis of rare disease, in an attempt to integrate sample-to-insight research with clinical testing for rare conditions.

The centerpiece of the agreement is the integration of Centogene's CentoMD database of 4.5 million clinically annotated phenotype and genotype variants of rare diseases into the Qiagen Clinical Insight bioinformatics platform and companion knowledge base.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.